Drug Approval | October 19, 2021
Dr Reddy’s Labs announces U.S. FDA approval for Lenalidomide capsules
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Equity raise to finance growth and investments in the biological space
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The platform will provide a safe and nurturing space for women, and non-binary individuals
The company plans to expand its portfolio in regulated markets aggressively
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Subscribe To Our Newsletter & Stay Updated
